HIGHLIGHTS
- who: Omar Hasan Ali from the Department of Medical Genetics, Life Sciences Institute, University of British Columbia, Vancouver, Canada have published the research: Fingolimod and tumor-infiltrating lymphocytes in checkpoint-inhibitor treated cancer patients, in the Journal: (JOURNAL)
- future: Large-scale studies and mechanistic explorations are necessary to substantiate these findings.
SUMMARY
Cancer Immunology, Immunotherapy 70:563-568 patients with newly diagnosed MS with a medical history of neoplasms. The authors present three patients, of whom one experienced a relapse of her melanoma and two developed new cancers during fingolimod treatment . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.